MedPath

The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome

Phase 2
Conditions
Postural Tachycardia Syndrome
Interventions
Registration Number
NCT01761825
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Brief Summary

The purpose of this study is to determine whether Ivabradine is an effective treatment for postural tachycardia syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients diagnosed with POTS by the following criteria:

    1. The presence of characteristic orthostatic symptoms of the POTS for at least six months.
    2. An increase in the heart rate of at least 30 beats per minute (without concomitant significant decrease in blood pressure of more than 20/10 mmHg) within 10 minutes after assuming a standing position (or during tilt test) on at least 3 separate occasions.
    3. No other concomitant diseases that could explain the symptoms of POTS.
Exclusion Criteria
<!-- -->
  1. History of systemic illness capable of affecting of affecting autonomic function (eg, diabetes mellitus, SLE).
  2. History of cardiovascular disease.
  3. History of smoking, drug or alcohol abuse.
  4. Pregnancy, and also uncontrolled thyroid or adrenal disorders.
  5. Using any drug metabolized by cytochrome P450 3A4 enzyme during the last 72 hours.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
IvabradineivabradineIvabradine 10 mg once
Primary Outcome Measures
NameTimeMethod
the change in heart rate after the administration of Ivabradine60 minutes , during the whole trial
the change in blood pressure after the administration of Ivabradine60 minutes
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath